… , oxaliplatin, irinotecan, and their combinations, but their administration presents several
serious disadvantages, such as poor bioavailability, lack of tumor … of pharmacologically active …

… other therapeutic cancer agents such as oxaliplatin, imiquimod, … The USFDA has
granted approval to 16 pharmacological … the tumor site, poor aqueous solubility, and dose-dependent …

… critical role in the variation of pharmacological efficacy, adverse effects, … oxaliplatin) are
another form of alkylating agents which are widely used for the treatment of many types of cancer…

… of 40 breast cancer patients before and after 13–21 days of dose escalating metformin (from …
Artemisinin (malaria treatment) derivatives may be an alternative to oxaliplatin, as they are …

… To be enrolled in this study each patient must meet all of the following criteria at the time of
… It demonstrated that a weekly dose escalating strategy (starting with 80 mg daily, escalating …

… In this study, EBV is more frequently associated with poor … , the liver function normalized in
one week. During further … Design: Phase I, open-label, dose-escalating study of a single 10 …

… from a patient with suspected SM directly at the district cancer detecting center at the patient’…
Prevalence and costs of s kin cancer treatment in the US, 2002–2006 and 2007–2011. Am J …

… cancer models and found effective as anti-cancer agents (152). Moreover, in vitro studies
revealed that these compounds impair … not affect their potency: oxaliplatin forms less crosslinks …

… tool for monitoring patients in a clinical setting. In a longitudinal study of ATL patients, we …
better estimate of molecular response in leukemia patients, the detection of refractoriness to …

… of cancer patients undergoing oxaliplatin-based chemotherapy. This retrospective study
included over 500 patients … cannabis exposure prior to oxaliplatin chemotherapy, b. cannabis …